LaVoieHealthScience Continues to Add to Public Company Client Roster

LaVoieHealthScience Continues to Add to Public Company Client Roster

Integrity Applications and Savara Pharmaceuticals Join LHS Portfolio of PR/IR Clients

Boston, MA – November 9, 2017 — LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced two additional public company clients, Integrity Applications and Savara Pharmaceuticals. These clients join a prestigious group of innovative health and science companies that are represented by LHS for their investor and/or public relations solutions.

Integrity Applications (OTCMKTS: IGAP), founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices.

Savara Pharmaceuticals (NASDAQ: SVRA), went public through a reverse merger with Mast Therapeutics in 2017. Based in West Lake Hills, TX, Savara is an emerging pharmaceutical development company focused on advancing a pipeline of novel inhalation therapies for the treatment of patients with rare pulmonary conditions. Savara has three investigational products in various stages of clinical development: Molgradex, the first inhaled product being developed for the treatment of patients with Pulmonary Alveolar Proteinosis and Nontuberculous Mycobacterial (NTM) Lung Infection; AeroVanc, an inhaled dry powder form of vancomycin to treat Methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients; and Aironite, which is inhaled via nebulizer to treat heart failure patients with preserved ejection fraction. Savara has an affiliate company based in Hørsholm, Denmark.

“Our integrated public and investor relations offerings, building on our team’s expertise is validated by these new client wins,” said Donna L. LaVoie, President & CEO of LaVoieHealthScience. “Each client has very specific business objectives in which our industry-tested strategic communications programs are being implemented. Aligning with true innovators in the health and science field is our passion.”

About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 29 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients, and is ranked among the 2017 Inc. 5000 list of fastest growing private companies for the fourth year. In addition to clients listed above, LaVoieHealthScience represents leaders such as Biotechnology Innovation Organization, Fusion Pharmaceuticals, Iota BioSciences, Landos Biopharma, LEO Science Hub, NewLink Genetics, Newron Pharmaceuticals, Origenis, Xontogeny LLC and other emerging health and science companies.

###

Media Contact:
Ryan Donovan
rdonovan@lavoiehealthscience.com
617-374-8800 x102